The results were consistent with earlier lab studies on human Her2-positive cancer cells: The H2.1MS1 silk gel particles loaded with doxorubicin selectively killed Her2-positive mouse cancer cells and significantly reduced tumor size over 20 days, with stronger effects at higher doses. The gene discussed is ERBB2; the disease is cancer.